Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/33632
Title: Renin-Angiotensin System Inhibition Following Transcatheter Aortic Valve Replacement
Authors: RODRIGUEZ-GABELLA, TaniaCATALA, PabloMUNOZ-GARCIA, Antonio J.NOMBELA-FRANCO, LuisVALLE, Raquel DelGUTIERREZ, EnriqueREGUEIRO, AnderJIMENEZ-DIAZ, Victor A.RIBEIRO, Henrique B.RIVERO, FernandoFERNANDEZ-DIAZ, Jose AntonioPIBAROT, PhilippeALONSO-BRIALES, Juan H.TIRADO-CONTE, GabrielaMORIS, CesarHOYO, Felipe Diez DelJIMENEZ-BRITEZ, GustavoZADERENKO, NicolasALFONSO, FernandoGOMEZ, ItziarCARRASCO-MORALEJA, ManuelRODES-CABAU, JosepCALVAR, J. Alberto San RomanAMAT-SANTOS, Ignacio J.
Citation: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, v.74, n.5, p.631-641, 2019
Abstract: BACKGROUND Several studies have demonstrated the benefits of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, but the presence of persistent fibrosis and myocardial hypertrophy has been related to worse prognosis. OBJECTIVES The aim of this study was to explore the potential benefits of renin-angiotensin system (RAS) inhibitors on left ventricular remodeling and major clinical outcomes following successful transcatheter aortic valve replacement (TAVR). METHODS Patients from 10 institutions with severe aortic stenosis who underwent TAVR between August 2007 and August 2017 were included. All baseline data were prospectively recorded, and pre-specified follow-up was performed. Doses and types of RAS inhibitors at discharge were recorded, and matched comparison according to their prescription at discharge was performed. RESULTS A total of 2,785 patients were included. Patients treated with RAS inhibitors (n = 1,622) presented similar surgical risk scores but a higher rate of all cardiovascular risk factors, coronary disease, and myocardial infarction. After adjustment for these baseline differences, reduction of left ventricular volumes and hypertrophy was greater and cardiovascular mortality at 3-year follow-up was lower (odds ratio: 0.59; 95% confidence interval: 0.41 to 0.87; p = 0.007) in patients treated with RAS inhibitors. Moreover, RAS inhibitors demonstrated a global cardiovascular protective effect with significantly lower rates of new-onset atrial fibrillation, cerebrovascular events, and readmissions. CONCLUSIONS Post-TAVR RAS inhibitors are associated with lower cardiac mortality at 3-year follow-up and offer a global cardiovascular protective effect that might be partially explained by a positive left ventricular remodeling. An ongoing randomized trial will help confirm these hypothesis-generating findings. (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185) (C) 2019 by the American College of Cardiology Foundation.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor


Files in This Item:
File Description SizeFormat 
art_RODRIGUEZ-GABELLA_ReninAngiotensin_System_Inhibition_Following_Transcatheter_Aortic_Valve_Replacement_2019.PDF
  Restricted Access
publishedVersion (English)1.12 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.